产品资料

重组人IL-36β, 157a.a.

如果您对该产品感兴趣的话,可以
产品名称: 重组人IL-36β, 157a.a.
产品型号: PP100054-500μg
产品展商: PERFEMIKER
产品价格: 22360.00 元
会员价格: 0.00 元
产品文档: 无相关文档
我要买:
产品已经成功添加到购物车
你添加了1件产品 查看购物车

简单介绍

名称:重组人IL-36β, 157a.a. 货号:PP100054 规格:500μg


重组人IL-36β, 157a.a.  的详细介绍

名称:重组人IL-36β, 157a.a.

Synonyms:FIL1 eta, IL-1 eta, IL-1F8, IL-1H2

Species:9

Accession:Q9NZH7-2

GeneID:27177

Source:Escherichia coli.

Molecular Weight:Approximately 17.7kDa, a single non-glycosylated polypeptide chain containing 157 amino acids.

Quantity:2µg/10µg/1000µg

AA Sequence:MNPQREAAPK SYAIRDSRQM VWVLSGNSLI AAPLSRSIKP VTLHLIACRD TEFSDKEKGN MVYLGIKGKD LCLFCAEIQG KPTLQLKEKN IMDLYVEKKA QKPFLFFHNK EGSTSVFQSV SYPGWFIATS TTSGQPIFLT KERGITNNTN FYLDSVE

Purity:> 97 % by SDS-PAGE and HPLC analyses.

Biological Activity:Fully biologically active when compared to standard. The specific activity is determined by its binding ability in a functional ELISA. Immobilized rHuIL-36β at 1 µg/mL can bind recombinant human IL-1 Rrp2 Fc Chimera with a range of 0.15-5 µg/mL.

Physical Appearance:Sterile Filtered White lyophilized (freeze-dried) powder.

Formulation:Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4.

Endotoxin:Less than 1 EU/μg of rHuIL-36β, 157a.a. as determined by LAL method.

Reconstitution:We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.

Stability & Storage:Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Reference:1. Nicklin MJ, Barton JL, Nguyen M, et al. 2002. Genomics. 79:718-25.
2. Dinarello C, Arend W, Sims J, et al. 2010. Nat Immunol. 11:973.
3. Magne D, Palmer G, Barton JL, et al. 2006. Arthritis Res Ther. 8:R80.
4. van Asseldonk EJ, Stienstra R, Koenen TB, et al. 2010. Obesity (Silver Spring). 18:2234-6.
5. Johnston A, Xing X, Guzman AM, et al. 2011. J Immunol. 186:2613-22.

Background:Interleukin-36 (IL-36) is a pro-inflammatory cytokine which plays an important role in the pathophysiology of several diseases. IL-36α, IL-36β, and IL-36γ (formerly IL-1F6, IL-1F8, and IL-1F9) are IL-1 family members that signal through the IL-1 receptor family members IL-1Rrp2 (IL-1RL2) and IL-1RAcP. IL-36 beta is reported to be expressed at higher levels in psoriatic plaques than in symptomless psoriatic skin or healthy control skin. Furthermore, it can stimulate production of interleukin-6 and interleukin-8 in synovial fibroblasts, articular chondrocytes and mature adipocytes. Two alternatively spliced transcript variants encode distinct (164 or 157 residues) protein isoforms that differ in their C-terminal 70 amino acid residues have been reported and IL-36β isoform 2 is synthesized as a 157 a.a. protein. Specifically, human IL-36β shares low sequence identity with IL-1β, IL-36RA, IL-36α and IL-36γ.